摘要
目的:研究膀胱癌组织EZH2和PTEN基因的表达,探讨其与膀胱癌临床病理特征及无瘤生存的关系。方法:制作80例膀胱移行细胞癌和10例正常膀胱黏膜(对照组)组织芯片,应用免疫组织化学方法检测EZH2和PTEN蛋白的表达,采用Kaplan-Meier单因素和Cox比例风险模型多因素分析其与膀胱癌无瘤生存的关系。结果:膀胱癌组织中EZH2和PTEN阳性表达率分别为80.0%和45.0%。EZH2和PTEN的阳性表达率在膀胱癌不同临床分期及病理分级组间存在显著性差异(P<0.05),且两者的表达呈负相关(P=0.033)。全组膀胱癌患者术后平均无瘤生存期为39.4个月,1、3、5年无瘤生存率分别为70.0%、55.2%、41.4%。单因素分析表明:病理分级、肿瘤数目和EZH2表达为影响膀胱癌预后的相关因素;多因素分析表明:病理分级、肿瘤数目和EZH2表达是膀胱癌复发的独立危险因素。结论:EZH2和PTEN异常表达与膀胱癌的发生、发展关系密切。病理分级、肿瘤数目和EZH2是膀胱癌预后的独立危险因素。
Objective： To investigate the expression and significance of EZH2 and PTEN in bladder transitional cell carcinoma （BTCC） and ascertain whether such expression is related to disease-free survival in patients with BTCC. Methods： The expression of EZH2 and PTEN was detected in a tumor tissue microarray consisting of 80 transitional cell carcinomas and 10 normal bladder mucosal tissues using immunohistochemistry. The predictive value of this expression for prognosis was investigated by Kaplan-Meier curves and Cox proportional hazards analysis in a multivariate model. Results： Expression of EZH2 and PTEN protein were detectable in 80.0% and 45.0% of bladder cancer specimens, respectively. The positive expression rates of EZH2 and PTEN showed a statistically significant difference in BTCC groups with different clinical stages and pathological grades （P〈0.05）. There was a negative correlation between EZH2 and PTEN expression （P= 0.033）. The mean postoperative disease-free survival time in BTCC patients was 39.4 months. The 1-, 3- and 5-year disease-free survival rates for the study population were 70.0%, 55.2% and 41.4%, respectively. Univariate analysis showed that pathological grade, tumor number and EZH2 expression were all significant prognostic factors. Multivariate analysis also identified pathological grade, tumor number and EZH2 expression as independent risk factors for disease-free survival. Conclusion： This retrospective study found that abnormal expression of EZH2 and PTEN may play an important role in the development and progression of BTCC. Additionally, expression of EZH2, as well as pathological grade and tumor number is a useful parameter for making a prognosis in patients with BTCC.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2010年第21期1220-1223,共4页
Chinese Journal of Clinical Oncology
